E16-Emergent and Translational Microbiology
Epidemiology and Public Health / IBS-E16 / Consolidated
Composed of researchers from the Microbiology Service of the Virgen de las Nieves University Hospital and the Microbiology Department of the University of Granada. It also has a Monardes Contract Investigator. The activity takes place in the Microbiology Service of the Virgin de las Nieves HU, where the Andalusian Virus Reference Laboratory is located; in the Faculty of Medicine of the UGR and in Genyo.
Research lines
- Involvement of infectious agents in diseases of uncertain etiology
- Multi-resistant microorganisms
- Emerging viruses in human pathology
Research networks
- RICET - Tropical Diseases Research Network
JOSE LUIS ROMERO BEJAR
MARIA IMMACULATE RAMIREZ MACIAS
ANGEL LINDE RODRIGUEZ
JAVIER RODRIGUEZ GRANGER
ANTONIO SAMPEDRO MARTINEZ
SARA LUISA SANBON MATSU GAMEZ
VICTORIA SANCHEZ-MARTIN
Mª LUISA SERRANO GARCIA
CARMEN GABRIELA SORIA SEGARRA
ANA DEL CARMEN SORIANO LERMA
ANTONIO SORLOZANO PORT
FERNANDO COBO MARTINEZ
JOSE ANTONIO GARCIA SALCEDO
JOSE GUTIERREZ FERNANDEZ
JOSE PATRICIO LINARES PALOMINO
Isaac Lopez Machado
JOSE MARIA NAVARRO MARI
MATILDE ORTIZ GONZALEZ
IRENE PEDROSA CORRAL
VIRGINIA PEREZ CARRASCO
MARIA ALBERTUZ CRESPO
Title: KIT, PROCEDURE AND APPARATUS FOR CONDITIONING BIOLOGICAL SAMPLES FOR CHROMATOGRAPHIC ANALYSIS
Code: P201330112
Inventors: Rodríguez Maresca, Manuel; Gutierrez Fernandez, Jose
Title: Bacterial resistance electronic guide
Code:GR-502-10
Exploring the root canal microbiome in previously treated teeth: A comparative study of diversity and metabolic pathways across two geographical locations
INTERNATIONAL ENDODONTIC JOURNAL, 2024;
FI: 5,4; D1
Identification of keystone taxa in root canals and periapical lesions of post-treatment endodontic infections: Next generation microbiome research
INTERNATIONAL ENDODONTIC JOURNAL, 2024;
FI: 5,4; D1
Compositional and functional analysis of the bacterial community of Mediterranean Leptosols under livestock grazing
SCIENCE OF THE TOTAL ENVIRONMENT, 2024;
FI: 8,2; D1
What are the translational challenges associated with Chagas disease drug discovery?
EXPERT OPINION ON DRUG DISCOVERY, 2024;
FI: 6; D1
Correlation between Inflammasomes and Microbiota in Peri-Implantitis
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024;
FI: 4,9; Q1
Comparative evaluation of MALDI-TOF MS and 16S rRNA gene sequencing for the identification of clinically relevant anaerobic bacteria. Critical evaluation of discrepant results
ANAEROBE, 2023;
FI: 2,3; Q4
Tuberculous otitis media: A case presentation and review of European literature
SPANISH MAGAZINE OF CHEMOTHERAPY, 2023;
FI: 1,9; Q4
Bacteremia caused by Clostridium sporogenes in an oncological patient
SPANISH MAGAZINE OF CHEMOTHERAPY, 2023;
FI: 1,9; Q4
New anaerobic bacteria causing infection: Bacteremia due to Murdochiella asaccharolytica
ANAEROBE, 2023;
FI: 2,3; Q4
Differences between bloodstream infections involving gram-positive and gram-negative anaerobes
ANAEROBE, 2023;
FI: 2,3; Q4
Parabacteroides goldsteinii abdominal infection in a patient with lymphoma
INFECTIOUS DISEASES NOW, 2022;
Curvicollide D Isolated from the Fungus Amesia sp. Kills African Trypanosomes by Inhibiting Transcription
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022;
FI: 6,208; Q1
Gallic Acid: A Natural Phenolic Compound Exerting Antitumor Activities in Colorectal Cancer via Interaction with G-Quadruplexes
CANCER, 2022;
FI: 6,575; Q1
Abnormal Alpha-1 Antitrypsin Levels and Other Risk Factors Associated with Lung Function Impairment at 6 and 12 Months after Hospitalization Due to COVID-19: A Cohort Study
HEALTHCARE, 2022;
FI: 3,16; Q2
Antimicrobial Susceptibility and Clinical Findings of Anaerobic Bacteria
ANTIBIOTICS-BASEL, 2022;
FI: 5,222; Q2
Antibacterial and Antifungal Activity of Propyl-Propane-Thiosulfinate and Propyl-Propane-Thiosulfonate, Two Organosulfur Compounds from Allium cepa: In Vitro Antimicrobial Effect via the Gas Phase
PHARMACEUTICALS, 2021;
FI: 5,863; Q1
Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021;
FI: 5,924; Q1
A Study in a Regional Hospital of a Mid-Sized Spanish City Indicates a Major Increase in Infection/Colonization by Carbapenem-Resistant Bacteria, Coinciding with the COVID-19 Pandemic
ANTIBIOTICS-BASEL, 2021;
FI: 4,639; Q2
Antimicrobial Activity of the Circular Bacteriocin AS-48 against Clinical Multidrug-Resistant Staphylococcus aureus
ANTIBIOTICS-BASEL, 2021;
FI: 4,639; Q2
Bacteremia caused by Anaerococcus SPP: Is this an underdiagnosed infection?
ANAEROBE, 2021;
FI: 3,331; Q3
An Updated Focus on Quadruplex Structures as Potential Therapeutic Targets in Cancer
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020;
FI: 4,556; Q1
A rare case of bacteremia caused by Propionibacterium (Propionimicrobium) lymphophilum
ANAEROBE, 2020;
FI: 2,709; Q3
Anaerobic bacteraemia: A score predicting mortality
ANAEROBE, 2020;
FI: 2,709; Q3
A propos of a new case of shigellosis by a non-imported multiresistant strain
SPANISH JOURNAL OF DIGESTIVE DISEASES, 2020;
FI: 2,196; Q4
Arcobacter butzleri and intestinal colonization
SPANISH MAGAZINE OF CHEMOTHERAPY, 2020;
FI: 1,132; Q4
Emergent genital infection by Leptotrichia trevisanii
INFECTION, 2019;
FI: 2,927; Q2
Asymptomatic Leishmania infection in blood donors from the Southern of Spain
INFECTION, 2019;
FI: 2,927; Q2
Preliminary readings of antimicrobial susceptibility panels: A simple, fast and inexpensive way to detect bacterial resistance and enhance antibiotic treatment of bloodstream infections.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2019;
FI: 2,314; Q3
Alloscardovia omnicolens emerging presence in premature rupture of membranes
NEW MICROBIOLOGY, 2019;
FI: 1,593; Q4
Prevalence among males from the general population of agents responsible for not ulcerative genital tract infections, assisted in specialized care
SPANISH MAGAZINE OF CHEMOTHERAPY, 2019;
FI: 0,76; Q4
Infections caused by Scedosporium / Lomentospora species: Clinical and microbiological findings in 21 cases
MEDICAL MYCOLOGY, 2018;
FI: 2,799; D1
West Nile virus outbreak in humans and epidemiological surveillance, West Andalusia, Spain, 2016
EUROSURVEILLANCE, 2018;
FI: 7,127; D1
Prevalence of pSCFS7-like vectors among cfr-positive staphylococcal population in Spain
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018;
FI: 4,253; Q1
Identification of Trypanosomatids by detecting Single Nucleotide Fingerprints using DNA analysis by dynamic chemistry with MALDI-ToF
TALANTA, 2018;
FI: 4,244; Q1
Comparison of PCR-based methods for the diagnosis of cutaneous leishmaniasis in two different epidemiological scenarios: Spain and Morocco.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018;
FI: 4,287; Q1
Two Cases of Neisseria meningitidis Proctitis in HIV-Positive Men Who Have Sex with Men
EMERGING INFECTIOUS DISEASES, 2017;
FI: 8,222; D1
Reduced accumulation of defective viral genomes contributes to severe outcome in influenza virus infected patients.
PLOS PATHOGENS, 2017;
FI: 6,608; D1
Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017;
FI: 4,302; Q1
Etiological and Resistance Profile of Bacteria Involved in Urinary Tract Infections in Young Children
BIOMED RESEARCH INTERNATIONAL, 2017;
FI: 2,476; Q2
Prevalence and genetic diversity of Trichomonas vaginalis in the general population of Granada and co-infections with Gardnerella vaginalis and Candida species.
JOURNAL OF MEDICAL MICROBIOLOGY, 2017;
FI: 2,159; Q3
Molecular characterization and antimicrobial susceptibility of hemolytic Streptococcus agalactiae from post-menopausal women.
MATURITAS, 2016;
FI: 2,942; Q1
Molecular characterization and antimicrobial susceptibility of hemolytic Streptococcus agalactiae from post-menopausal women.
MATURITAS, 2016;
FI: 3,12; Q1
Chronic bacterial prostatitis. Clinical and microbiological study of 332 cases
CLINICAL MEDICINE, 2016;
FI: 1,267; Q2
Actinotignum schaalii (formerly Actinobaculum schaalii): A new cause of balanitis
CLINICAL MEDICINE, 2016;
FI: 1,267; Q2
Proctitis in an HIV-infected male who has sex with men
CLINICAL MEDICINE, 2016;
FI: 1,267; Q2
Potential Relevance of Melatonin Against Some Infectious Agents: A Review and Assessment of Recent Research
CURRENT MEDICINAL CHEMISTRY, 2015;
FI: 3,853; D1
Performances from the laboratory to improve the clinical use of cefepime
AMERICAN JOURNAL OF INFECTION CONTROL, 2015;
FI: 2,206; Q2
Comparison of epidemiology and clinical characteristics of infections by human parechovirus vs. those by enteroviruses during the first month of life
EUROPEAN JOURNAL OF PEDIATRICS, 2015;
FI: 1,89; Q2
Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection.
GENES AND IMMUNITY, 2015;
FI: 2,913; Q2
Analytical performance of the automated multianalyte point-of-care mariPOC(R) for the detection of respiratory viruses
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2015;
FI: 2,457; Q3
E_PI01_2024 MARIA IMMACULADA RAMIREZ MACIAS (E16)
Funder: FIBAO Foundation
File number: E_PI01_2024
Execution time: 11/12/2024 - 31/12/2025
IP: MARIA INMACULADA RAMIREZ MACIAS
New targets and designs to improve CAR-T cell based immunotherapy against pancreatic cancer CarPanTu
Funder: STATE RESEARCH AGENCY - PRTR
File number: PLEC2021-008094 - FIBAO
Execution time: 01/10/2021 - 30/09/2024
IP: JOSE ANTONIO GARCIA SALCEDO
Humoral and cellular immune response to SARS-Cov2 mRNA vaccines (BNT 162b2 and mRNA-1273) and its relationship with HLA polymorphism and the microbiome
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI21 / 01708
Execution time: 01/01/2022 - 31/12/2024
IP: FERNANDO COBO MARTINEZ
Production of therapeutic antibodies for the treatment of COVID-19
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI21 / 00497
Execution time: 01/01/2022 - 31/12/2024
IP: JOSE ANTONIO GARCIA SALCEDO
I-MOVE-COVID-19 - Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic
Funder: EUROPEAN COMMISSION
File number: I-MOVE-COVID-19
Execution time: 16/03/2020 - 15/06/2022
IP: I-MOVE-COVID-19 - Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic
SAF2015-71714-R - R & D CHALLENGES - JOSE A GARCIA SALCEDO - DEVELOPMENT OF A THERAPY BASED ON NANO-ANTIBODIES AGAINST FLU VIRUSES
Funder: MINISTRY OF ECONOMY AND COMPETITIVENESS
File number: SAF2015-71714-R
Execution time: 01/01/2016 - 31/12/2018
IP: JOSE ANTONIO GARCIA SALCEDO
Nanosystems conjugated with antibody fragments for treating brain infections
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: AC18 / 00008
Execution time: 01/01/2019 - 31/12/2021
IP: JOSE ANTONIO GARCIA SALCEDO
RD16 / 0027/0012 - RICET - JOSE M NAVARRO
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: RD16 / 0027/0012
Execution time: 01/01/2017 - 31/12/2021
IP: JOSE MARIA NAVARRO MARI
3TR - Taxonomy, Treatment, Targets and Remission: Identification of the Molecular Mechanisms of non-response to Treatments, relapses and remission in Autoimmune Inflammatory Conditions
Funder: EUROPEAN COMMISSION
File number: 3TR-831434 SAS FIBAO
Execution time: 01/06/2019 - 31/05/2026
IP: JOSE ANTONIO GARCIA SALCEDO
Inhaled corticosteroid dose escalation vs triple therapy in patients with T2-high asthma not controlled by medium doses of inhaled corticosteroid/long-acting beta-agonist combination: a real-life study. TRICORDA (Triple vs.
Funder: LUIS PEREZ DE LLANO
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 27/03/2023 - 30/09/2024
IP: CONCEPTION MORALES GARCIA
A Randomized, Double-Blind, Placebo-Controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-2)
Funder: United Therapeutics Corporation
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 30/09/2022 - 30/05/2025
PI: ANA DOLORES ROMERO ORTIZ
Clinical and Epidemiology of the outbreak of Monkeypox infection in Spain in 2022. CEME STUDY 22
Funder: SEIMC-GESIDA FOUNDATION
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 17/11/2022 - 30/03/2023
IP: SARA LUISA SANBONMATSU GAMEZ
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Financier: BOEHRINGER INGELHEIM ESPAÑA, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 12/12/2022 - 30/04/2025
PI: ANA DOLORES ROMERO ORTIZ
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)
Funder: GLAXOSMITHKLINE RESEARCH DEVELOPMENT LTD
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 13/12/2022 - 31/10/2025
IP: CONCEPTION MORALES GARCIA
Randomized, double-blind, parallel-group, multicenter, 24-week trial to evaluate the efficacy and safety of budesonide and formoterol fumarate metered-dose inhaler compared to budesonide metered-dose inhaler and Symbicort® open-arm Turbohaler® pressurized metered dose inhaler in patients with poorly controlled asthma (VATHOS).
Funder: ASTRAZENECA FARMACEUTICA ESPAÑA SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 10/06/2022 - 30/11/2023
IP: CONCEPTION MORALES GARCIA
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Financier: BOEHRINGER INGELHEIM ESPAÑA, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 05/12/2022 - 28/02/2025
PI: ANA DOLORES ROMERO ORTIZ
Open-label, multicenter, single-arm extension study to evaluate the long-term safety of GSK3511294 (depemokimab) in adult and adolescent participants with severe asthma with eosinophilic phenotype from studies 206713 or 213744 (AGILE)
Funder: GLAXOSMITHKLINE RESEARCH DEVELOPMENT LTD
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 07/03/2022 - 30/06/2025
IP: CONCEPTION MORALES GARCIA
Prospective observational study to assess the effect of extrafine fixed triple therapy on symptom control and adherence to treatment in patients with moderate or severe COPD in routine clinical practice conditions (TRIATH Study
Financer: CHIESI ESPAÑA, SA
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 25/06/2021 - 28/02/2023
IP: CONCEPTION MORALES GARCIA
Phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with idiopathic pulmonary fibrosis
Financier: ROCHE FARMA, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 26/03/2021 - 20/06/2023
PI: ANA DOLORES ROMERO ORTIZ
Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Financier: ROCHE FARMA, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 21/06/2021 - 21/06/2023
PI: ANA DOLORES ROMERO ORTIZ
A 52-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma
Funder: GLAXOSMITHKLINE RESEARCH DEVELOPMENT LTD
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 21/07/2021 - 30/09/2023
IP: CONCEPTION MORALES GARCIA
52-week, randomized, double-blind, double-dummy, parallel-group, multicenter, non-inferiority study to assess exacerbation rate, additional measures of asthma control, and participant safety
Funder: GLAXOSMITHKLINE RESEARCH DEVELOPMENT LTD
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 20/07/2021 - 30/12/2023
IP: CONCEPTION MORALES GARCIA
Phase I Open-label, First-in-human Study to Evaluate Feasibility and Safety of Tissue Engineered Veins in Patients With Chronic Venous Insufficiency.
Financer: VERIGRAFT IBERIA, SL
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 09/09/2021 - 30/12/2023
IP: JOSE PATRICIO LINARES PALOMINO
Open-label, multicenter clinical trial to evaluate the effectiveness and safety of intravenous tocilizumab in the treatment of patients with COVID-19 pneumonia: the BREATH-19 study.
Funder: SEIMC-GESIDA FOUNDATION
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 14/08/2020 - 30/08/2020
PI: ANA DOLORES ROMERO ORTIZ
